Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.
Biochemical recurrence
European Association of Urology
Gleason score
Guidelines
PSA kinetics
Prognostic factors
Prostate cancer
Radical prostatectomy
Radiotherapy
Journal
European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661
Informations de publication
Date de publication:
15 03 2020
15 03 2020
Historique:
received:
23
04
2019
revised:
05
05
2019
accepted:
05
06
2019
pubmed:
30
6
2019
medline:
21
5
2021
entrez:
29
6
2019
Statut:
ppublish
Résumé
Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.
Identifiants
pubmed: 31248850
pii: S2405-4569(19)30159-2
doi: 10.1016/j.euf.2019.06.004
pii:
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-234Informations de copyright
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.